CN1142918C - 新的羧酸衍生物,其制备和应用 - Google Patents

新的羧酸衍生物,其制备和应用 Download PDF

Info

Publication number
CN1142918C
CN1142918C CNB951956558A CN95195655A CN1142918C CN 1142918 C CN1142918 C CN 1142918C CN B951956558 A CNB951956558 A CN B951956558A CN 95195655 A CN95195655 A CN 95195655A CN 1142918 C CN1142918 C CN 1142918C
Authority
CN
China
Prior art keywords
alkyl
phenyl
ome
methyl
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB951956558A
Other languages
English (en)
Chinese (zh)
Other versions
CN1160396A (zh
Inventor
H
H·里彻尔斯
�����ּ�����˾
D·克林吉
W·埃姆伯格
�ָ���
A·克林格
S·莫勒
E·鲍曼
��Ĭ����
J·莱因海默
�ָ���ͳ�
U·J·沃格尔巴彻
W·沃奈特
L·昂格尔
M·拉沙克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ebert GmbH and Co KG
Original Assignee
BASF SE
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6530833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1142918(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE, Abbott GmbH and Co KG filed Critical BASF SE
Publication of CN1160396A publication Critical patent/CN1160396A/zh
Application granted granted Critical
Publication of CN1142918C publication Critical patent/CN1142918C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CNB951956558A 1994-10-14 1995-10-07 新的羧酸衍生物,其制备和应用 Expired - Lifetime CN1142918C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4436851.8 1994-10-14
DE4436851 1994-10-14
DE19533023A DE19533023B4 (de) 1994-10-14 1995-09-07 Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19533023.4 1995-09-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2004100027833A Division CN1293059C (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用
CN2006100999548A Division CN1923820B (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用

Publications (2)

Publication Number Publication Date
CN1160396A CN1160396A (zh) 1997-09-24
CN1142918C true CN1142918C (zh) 2004-03-24

Family

ID=6530833

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2006100999548A Expired - Lifetime CN1923820B (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用
CNB2004100027833A Expired - Lifetime CN1293059C (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用
CNB951956558A Expired - Lifetime CN1142918C (zh) 1994-10-14 1995-10-07 新的羧酸衍生物,其制备和应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN2006100999548A Expired - Lifetime CN1923820B (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用
CNB2004100027833A Expired - Lifetime CN1293059C (zh) 1994-10-14 1995-10-07 新的羧酸衍生物，其制备和应用

Country Status (31)

Country Link
US (15) US5932730A (enExample)
EP (2) EP1110952B9 (enExample)
JP (6) JP3957748B2 (enExample)
KR (1) KR100438339B1 (enExample)
CN (3) CN1923820B (enExample)
AT (2) ATE204568T1 (enExample)
BR (1) BR9509338A (enExample)
CA (1) CA2201785C (enExample)
CZ (1) CZ294603B6 (enExample)
DE (4) DE19533023B4 (enExample)
DK (1) DK0785926T3 (enExample)
ES (2) ES2226996T3 (enExample)
FI (1) FI120492B (enExample)
FR (1) FR08C0041I2 (enExample)
GR (1) GR3036931T3 (enExample)
HR (2) HRP950517B1 (enExample)
HU (1) HU220621B1 (enExample)
IL (1) IL115560A (enExample)
LU (1) LU91487I2 (enExample)
MX (1) MX9702658A (enExample)
NL (1) NL300361I2 (enExample)
NO (2) NO308846B1 (enExample)
NZ (1) NZ294849A (enExample)
PL (1) PL186850B1 (enExample)
PT (1) PT785926E (enExample)
RU (1) RU2180335C2 (enExample)
SI (1) SI9520110A (enExample)
TW (1) TW577880B (enExample)
UA (1) UA45985C2 (enExample)
WO (1) WO1996011914A1 (enExample)
ZA (1) ZA958642B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
CN104592129A (zh) * 2013-10-30 2015-05-06 武汉启瑞药业有限公司 一种改进的制备安立生坦的方法
CN106699626A (zh) * 2015-11-13 2017-05-24 辽宁远大诺康生物制药有限公司 一种2-羟基-3-甲氧基-3,3-二苯基丙酸盐消旋体的制备方法

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19536891A1 (de) * 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
AU740351B2 (en) 1996-12-18 2001-11-01 Abbott Gmbh & Co. Kg Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
JP2001514254A (ja) * 1997-09-04 2001-09-11 ビーエーエスエフ アクチェンゲゼルシャフト 新規カルボン酸誘導体、その製造及び混合ｅｔａ／ｅｔｂエンドセリン受容体拮抗薬としてのその使用
EP1014989B1 (de) * 1997-09-26 2004-01-14 Abbott GmbH & Co. KG Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
DE19743143A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
US6509341B1 (en) * 1997-10-31 2003-01-21 Abbott Laboratories Carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
DE19750529A1 (de) * 1997-11-14 1999-05-20 Basf Ag Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19809635A1 (de) * 1998-03-06 1999-09-09 Basf Ag Verfahren zur Darstellung von Endothelinrezeptorantagonisten vom Sulfanyltyp
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE10002393A1 (de) * 2000-01-20 2001-07-26 Basf Ag Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US6772708B2 (en) * 2001-10-30 2004-08-10 The Procter And Gamble Company Wetness indicator having improved colorant retention
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
DE102005025161A1 (de) * 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
EP2118073A2 (en) * 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
US20090069353A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched ambrisentan
DE102008037324A1 (de) 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
WO2010070658A2 (en) * 2008-11-05 2010-06-24 Msn Laboratories Limited Improved process for the preparation of endothelin receptor antagonists
DE202009009917U1 (de) 2009-07-21 2010-02-11 Ratiopharm Gmbh Ambrisentan in spezifischer kristalliner Form
WO2010091877A2 (en) 2009-02-13 2010-08-19 Ratiopharm Gmbh Process for producing ambrisentan
WO2011004402A2 (en) 2009-07-10 2011-01-13 Cadila Healthcare Limited Improved process for the preparation of ambrisentan and novel intermediates thereof
US20110046163A1 (en) * 2009-08-20 2011-02-24 Moore Ii Bob M Furanopyrimidine cannabinoid compounds and related methods of use
AU2010328234B2 (en) * 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CA2792473A1 (en) * 2010-03-15 2011-09-22 Natco Pharma Limited A process for the preparation of highly pure ambrisentan
WO2012017441A1 (en) 2010-08-04 2012-02-09 Natco Pharma Limited Improved process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
EP2476670A1 (en) 2011-01-07 2012-07-18 Zentiva, K.S. Stable solid salts of ambrisentan
CN102276536B (zh) * 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103012280B (zh) * 2011-09-22 2015-04-29 江苏康缘药业股份有限公司 一种制备安立生坦的方法
KR101855506B1 (ko) 2011-10-13 2018-05-08 주식회사 동진쎄미켐 방향족 고리 함유 고분자 및 이를 포함하는 레지스트 하층막 조성물
EP2768811A1 (en) 2011-10-19 2014-08-27 Cipla Limited Process for the preparation of an endothelin receptor antagonist
HRP20161438T1 (hr) 2012-06-29 2016-12-16 Kern Pharma, S.L. Postupak pripreme derivata karboksilne kiseline i njihovih intermedijera
CN103524425A (zh) * 2012-07-04 2014-01-22 天津药物研究院 一种安立生坦的晶型v及其制备方法和应用
CN103524424A (zh) * 2012-07-04 2014-01-22 天津药物研究院 一种安立生坦的晶型vi及其制备方法和应用
CN104098462B (zh) * 2013-04-12 2017-11-17 江苏豪森药业集团有限公司 2‑羟基‑3‑甲氧基‑3,3‑二苯基丙酸消旋物的拆分方法
CN103709106A (zh) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 一种立体选择性制备安立生坦的方法
CN104744231A (zh) * 2013-12-26 2015-07-01 天津药物研究院 一种拆分2-羟基丙酸消旋体的方法
CN105801404B (zh) * 2014-12-31 2019-01-08 辽宁远大诺康生物制药有限公司 一种s-2-羟基-3-甲氧基-3,3-二苯基丙酸及其制备方法
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
CN109705042B (zh) * 2017-10-26 2021-12-21 正大天晴药业集团股份有限公司 一种安立生坦的制备方法
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE403578C (de) 1924-10-02 Walter Beige Verfahren zum Innen-Emaillieren von Roehren
JPS5729445B2 (enExample) 1974-06-25 1982-06-23
GB8912700D0 (en) 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
JP2771604B2 (ja) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 除草剤及びその有効成分となる新規なアルカン酸誘導体
EP0347811B1 (en) * 1988-06-20 1994-03-30 Kumiai Chemical Industry Co., Ltd. Alkanoic acid derivatives and herbicidal compositions
JPH0331266A (ja) 1989-06-27 1991-02-12 Nissan Chem Ind Ltd ピリミジン誘導体及び除草剤
IL94999A (en) 1989-07-19 1994-10-07 Schering Ag alpha-pyrimidinyloxy (thio)- and alpha-triazinylo xy (thio) carboxylic acid derivatives and herbici dal compositions containing the same
US5270289A (en) 1989-07-19 1993-12-14 Schering Aktiengesellschaft Herbicidal dimethoxy pyrimidinyloxy-fluorinated acids and salts
FR2650365B1 (fr) 1989-07-28 1991-11-22 Caillau Ets Raccord rapide
JPH03240777A (ja) 1990-02-20 1991-10-28 Ube Ind Ltd 脂肪酸誘導体、その製造法及び除草剤
DE4029648A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JPH05125058A (ja) * 1990-10-19 1993-05-21 Ube Ind Ltd ３−アルコキシアルカン酸化合物、その中間体、その製造法及び除草剤
CA2053603A1 (en) * 1990-10-19 1992-04-20 Katsumasa Harada 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same
DE4035758A1 (de) 1990-11-08 1992-05-14 Schering Ag Substituierte (alpha)-pyrimidinyloxy(thio)- und (alpha)-triazinyloxy(thio)-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
JP2730021B2 (ja) 1991-05-31 1998-03-25 宇部興産株式会社 ３−ベンジルオキシアルカン酸誘導体、その製造法及び除草剤
DE69226813T2 (de) 1991-06-07 1999-02-18 Ube Industries, Ltd., Ube, Yamaguchi Pyrimidin- oder Triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Herbizide
JP2730022B2 (ja) * 1991-06-07 1998-03-25 宇部興産株式会社 ３−アルコキシブチリルイミダゾール誘導体、その製造法及び除草剤
DE4123469A1 (de) 1991-07-16 1993-01-21 Basf Ag Herbizide mittel, die n-dichloracetyl-diazacycloalkane als antagonistische verbindungen enthalten
EP0618909A1 (de) * 1991-12-10 1994-10-12 Hoechst Schering AgrEvo GmbH Pyrimidinyl- oder triazinyl-oxy-(oder -thio)-aldehydderivate, und verwendung als herbizide oder pflanzenwachstumsregulatoren
DE4142570A1 (de) 1991-12-21 1993-06-24 Basf Ag Glykolaldehyd- und milchsaeurederivate, deren herstellung und verwendung
DE4201875A1 (de) 1992-01-24 1993-07-29 Basf Ag Thiocarbonsaeurederivate, verfahren und zwischenprodukte zu ihrer herstellung
US5376620A (en) 1992-04-17 1994-12-27 Ube Industries, Ltd. Sulfonamide derivative, process for preparing the same and herbicide using the same
US5482920A (en) * 1992-06-17 1996-01-09 Ciba-Geigy Corporation Triazinyl compounds with herbicidal activity
US5541148A (en) 1992-07-08 1996-07-30 Ciba-Geigy Corporation Selective safened herbicidal composition comprising 2-ethoxycarbonyl-3-(4,6-dimethoxypyrimidine-2-yl) oxy-pyridine and an acylsulfamoylphenyl-urea safener
EP0671880A1 (en) 1992-07-08 1995-09-20 Ciba-Geigy Ag Selective herbicidal composition
JP2985992B2 (ja) 1992-07-21 1999-12-06 宇部興産株式会社 ３−アルコキシ−ｎ−シクロアルキルスルホニルアルカン酸アミド誘導体、その製造法及び除草剤
DE4313413A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
EP0627472B1 (en) * 1993-06-03 2000-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Curable composition
DE4335950A1 (de) * 1993-10-21 1995-04-27 Basf Ag Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung
DE4411225A1 (de) 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
AU2882195A (en) 1994-06-27 1996-01-19 Ciba-Geigy Ag Pyrimidinyl- and triazinyl-oxy and thio-3-haloalkyl-propionic acid derivatives as herbicides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
WO1996012515A2 (en) 1994-10-21 1996-05-02 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator and process for forming the same
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
EP1014989B1 (de) 1997-09-26 2004-01-14 Abbott GmbH & Co. KG Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
DE19850301A1 (de) 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE10002393A1 (de) 2000-01-20 2001-07-26 Basf Ag Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern
CN101491028A (zh) 2006-07-12 2009-07-22 华为技术有限公司 用于控制拥塞的方法
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
CN104592129A (zh) * 2013-10-30 2015-05-06 武汉启瑞药业有限公司 一种改进的制备安立生坦的方法
CN104592129B (zh) * 2013-10-30 2019-04-16 武汉启瑞药业有限公司 一种改进的制备安立生坦的方法
CN106699626A (zh) * 2015-11-13 2017-05-24 辽宁远大诺康生物制药有限公司 一种2-羟基-3-甲氧基-3,3-二苯基丙酸盐消旋体的制备方法
CN106699626B (zh) * 2015-11-13 2019-08-16 辽宁远大诺康生物制药有限公司 一种2-羟基-3-甲氧基-3,3-二苯基丙酸盐消旋体的制备方法

Also Published As

Publication number Publication date
EP1110952B9 (de) 2004-12-15
USRE42462E1 (en) 2011-06-14
FR08C0041I2 (enExample) 2009-12-18
HU220621B1 (hu) 2002-03-28
US20120088911A1 (en) 2012-04-12
FI971529A0 (fi) 1997-04-11
NO2008015I2 (no) 2012-03-05
ES2162942T3 (es) 2002-01-16
JP3957748B2 (ja) 2007-08-15
US20040092742A1 (en) 2004-05-13
CZ113297A3 (cs) 1998-03-18
PL319655A1 (en) 1997-08-18
US5969134A (en) 1999-10-19
ATE204568T1 (de) 2001-09-15
NZ294849A (en) 1999-04-29
US20060276645A1 (en) 2006-12-07
DE59509541D1 (de) 2001-09-27
KR100438339B1 (ko) 2004-08-25
KR970707103A (ko) 1997-12-01
US7109205B2 (en) 2006-09-19
US20100076188A1 (en) 2010-03-25
US20060160808A1 (en) 2006-07-20
JP4512105B2 (ja) 2010-07-28
FR08C0041I1 (enExample) 2008-11-28
FI120492B (fi) 2009-11-13
JP2007169295A (ja) 2007-07-05
EP1110952B1 (de) 2004-09-29
HRP20040364A2 (en) 2005-06-30
ES2226996T3 (es) 2005-04-01
HK1104293A1 (zh) 2008-01-11
NO308846B1 (no) 2000-11-06
AU688611B2 (en) 1998-03-12
HRP20040364B1 (en) 2006-09-30
JP2007137893A (ja) 2007-06-07
JP2007126488A (ja) 2007-05-24
RU2180335C2 (ru) 2002-03-10
MX9702658A (es) 1997-06-28
JP4512106B2 (ja) 2010-07-28
CN1293059C (zh) 2007-01-03
US6197958B1 (en) 2001-03-06
ZA958642B (en) 1997-04-14
JPH10507190A (ja) 1998-07-14
AU3804595A (en) 1996-05-06
USRE42477E1 (en) 2011-06-21
CN1160396A (zh) 1997-09-24
PL186850B1 (pl) 2004-03-31
CA2201785C (en) 2006-08-29
NL300361I1 (nl) 2008-12-01
IL115560A (en) 2003-02-12
DE19533023A1 (de) 1996-04-18
PT785926E (pt) 2002-02-28
JP2007137892A (ja) 2007-06-07
GR3036931T3 (en) 2002-01-31
TW577880B (en) 2004-03-01
DE19533023B4 (de) 2007-05-16
EP0785926B1 (de) 2001-08-22
EP0785926A1 (de) 1997-07-30
IL115560A0 (en) 1996-01-19
HRP950517A2 (en) 1997-10-31
HRP950517B1 (en) 2004-06-30
JP4787184B2 (ja) 2011-10-05
NO2008015I1 (no) 2008-11-03
US8349843B2 (en) 2013-01-08
JP5700378B2 (ja) 2015-04-15
ATE277911T1 (de) 2004-10-15
CN1923820B (zh) 2010-04-21
LU91487I2 (fr) 2008-12-15
US20130317044A1 (en) 2013-11-28
DE59510949D1 (de) 2004-11-04
CA2201785A1 (en) 1996-04-25
US20020052495A1 (en) 2002-05-02
US20060276474A1 (en) 2006-12-07
DE122008000049I1 (de) 2009-01-29
US7863445B2 (en) 2011-01-04
SI9520110A (en) 1997-12-31
US20070203338A1 (en) 2007-08-30
NO971675L (no) 1997-06-10
HK1066541A1 (en) 2005-03-24
US20110178294A1 (en) 2011-07-21
US5932730A (en) 1999-08-03
EP1110952A1 (de) 2001-06-27
US7601730B2 (en) 2009-10-13
CN1513844A (zh) 2004-07-21
CZ294603B6 (cs) 2005-02-16
UA45985C2 (uk) 2002-05-15
US7119097B2 (en) 2006-10-10
US6600043B2 (en) 2003-07-29
BR9509338A (pt) 1997-11-04
US7582647B2 (en) 2009-09-01
DK0785926T3 (da) 2001-10-08
NO971675D0 (no) 1997-04-11
NL300361I2 (nl) 2009-02-02
CN1923820A (zh) 2007-03-07
JP5160797B2 (ja) 2013-03-13
FI971529L (fi) 1997-04-11
WO1996011914A1 (de) 1996-04-25
HUT77443A (hu) 1998-04-28
JP2012111772A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
CN1142918C (zh) 新的羧酸衍生物,其制备和应用
CN1036920C (zh) 含杂环碳酸衍生物
US9850214B2 (en) Inhibitors of NEDD8-activating enzyme
CN1608050A (zh) 哌嗪衍生物
CN1040980C (zh) 第二信使细胞信号传送抑制剂
CN1234029A (zh) 色烯－3－羚酸衍生物
CN1148807A (zh) 用作药物的嘧啶或三嗪羧酸衍生物
US6030975A (en) Carboxylic acid derivatives, their preparation and use in treating cancer
CN1711248A (zh) 嘧啶－磺酰胺及其作为内皮素受体拮抗剂的应用
HK1066541B (en) New carboxylic acid derivatives, their preparation and their use
CN1665506A (zh) 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
CN1555358A (zh) Ccr-3受体拮抗剂v
HK1047102A1 (zh) 新的具有芳香基取代的氮雜環的羧酸衍生物、其製備和作為內皮素受體拮抗劑的應用
HK1027754A (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer
CN1044813A (zh) 钙拮抗药
HK1048317A (en) Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
CN1481379A (zh) 作为ccr-3受体拮抗剂的取代的吡咯烷
CN1223115A (zh) 含喹啉和喹唑啉衍生物的药用组合物及其新化合物
CN1292782A (zh) 新的不对称取代的羧酸衍生物、其制备方法以及其作为混合eta/etb受体拮抗剂的应用
HK1104293B (en) New carboxylic acid derivatives, their preparation and their use
CN1156443A (zh) 苯并环烯化合物及它们的制备和用途
HK1019599A (en) Novel carboxylic acid derivatives, their preparation and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: AVECIA BIOLOGY TECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: BASF AKTIENGESELLCHAFT

Effective date: 20030509

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030509

Address after: Wiesbaden, Federal Republic of Germany

Applicant after: Ebert GmbH & Co. KG

Address before: Ludwigshafen, Federal Republic of Germany

Applicant before: Basf AG

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040324

EXPY Termination of patent right or utility model